UTIs can be painful, and they’re not something people like to talk about. But they happen often, affecting an estimated 60% of women and 20% of men in their lifetimes. While we might view these ...

Jyong Biotech Ltd. filed for an IPO that could raise as much as $40 million to advance a pipeline that includes several prospects for urinary system disorders, including one that has reached the NDA ...

AIE is a unique photophysical phenomenon, and its distinctive luminescence properties have demonstrated significant potential in the biomedical field. In urinary system diseases, AIE materials, with ...

Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large ...

MCS-8 is developed using Jyong Biotech’s core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, ...

Jyong Biotech Ltd., a Taiwan-based biotechnology company focused on developing innovative plant-derived drugs for urinary system diseases, announced the closing of its initial public offering (IPO) on ...

Based on: Diseases of the Bladder, Prostate Gland, and Urethra, including a Practical View of Urinary Diseases, Deposits, and Calculi. Being the fourth edition of The Irritable Bladder, revised and ...